Mechanisms that determine drug sensitivity of distinct cancer types is poorly understood for most cytotoxic chemotherapy. In this study, we elucidated a new resistance mechanism to DNA damaging chemotherapeutic through modulation of p53 dynamics. While both sensitive and resistant cancer cell lines activated similar p53 oscillation followed by cell-cycle arrest in response to low dose of DNA damaging drug, they switched in a bimodal manner to monotonic or single pulse dynamics at high drug dose. Cell lines with monotonically increasing p53 underwent rapid and extensive drug-induced apoptosis, while those exhibiting a single p53 pulse mostly survived. By combining single cell imaging with computational modeling, we characterized a regulatory module involving ATM, p53, Mdm2 and Wip1, which generates bimodal p53 dynamics through coupled feed-forward and feedback, and we found that basal expression of ATM determined the differential modular output between drug sensitive and resistant lines. Moreover, we showed combinatorial inhibition of Mdm2 and Wip1 was an effective strategy to alter p53 dynamics in resistant cancer cells and sensitize their apoptotic response. Our results point to p53 pulsing as a potentially druggable mechanism that mediates resistance to cytotoxic chemotherapy.
Introduction
Tumors exhibit large intrinsic variation in drug responsiveness due to both intra-tumoral and inter-tumoral heterogeneity; and previously sensitive tumors commonly evolve to be drug resistant during chemotherapy. In order to improve therapy, we need better understanding of both intrinsic and acquired drug resistance. Most characterized and known mechanisms of drug resistance involve genetic mutation, such as mutation of drug target genes for kinase inhibitors and mutation of genes that mediate drug responses, e.g. p53 for DNA damaging drugs [1, 2] .
However, for most commonly used cytotoxic chemotherapy, the mechanistic basis of drug sensitivity is unclear at both genotype and phenotype levels.
The p53 pathway, consisting of the tumor suppressor protein p53, its upstream regulators and downstream target genes, plays a central role in mediating cellular response to DNA damaging chemotherapeutics [3] [4] [5] . Loss of p53 function due to p53 mutation has been widely studied with respect to tumor resistance to DNA damaging drugs. However, resistance is often seen, and may be even greater, in tumors with wild-type p53 for unclear reasons [6] [7] [8] . Extensive biochemical and cell biology studies have revealed p53 activity is regulated by multiple posttranslational modifications [9, 10] , differential subcellular localization [11] , and interaction with co-factors [12] . Drug resistance may arise from all of these venues. More recently, single cell studies both by us and others showed that alteration of the induction dynamics of p53 is another mechanism to modulate p53 activity, raising the interesting possibility of a mechanistic link between p53 dynamics and drug sensitivity [13, 14] .
The control of p53 dynamics in response to DNA damage was first examined for transient gamma or UV irradiation and revealed intriguing oscillation of p53 level that culminated in cell-cycle arrest and senescence, but not cell death [15] [16] [17] [18] . Moreover, a recent study of a cancer cell line panel showed damage-induced p53 dynamics varied significantly between cell lines [19] . However, cell-cycle arrest remained the dominant damage response phenotype, despite the difference of p53 dynamics in the distinct cell lines. The lack of cell death response in these previous studies was probably due to the low level of DNA damage used. By examining a much larger dose range of DNA damage triggered by a DNA damaging chemotherapeutic, etoposide, we uncovered a new dynamical regime of p53 activation at high DNA damage, i.e., monotonic induction, which triggers cell death by enhancing p53 activation level and pro-apoptotic activity [13] . We further showed that changing p53 dynamics from oscillation to monotonic increase was sufficient to switch response from cell-cycle arrest to apoptosis in drug sensitive cell lines, confirming the role of bimodal p53 dynamics in regulating differential phenotypic response, i.e., cell-cycle arrest vs. death, to DNA damage. However, it left unexplained the role of p53 dynamics in drug resistance, in particular resistance to druginduced cell death that is critical for therapeutic efficacy.
We thus set out to compare single-cell p53 dynamics of cancer cell lines that are intrinsically sensitive vs. resistant to DNA damaging drugs. Intriguingly, we observed cell-type dependent bimodal regulation of p53 dynamics that correlates with sensitivity to drug-induced apoptosis. Cell lines sensitive to etoposide, such as U-2 OS and A549, switched from oscillatory p53 to strong monotonic p53 induction followed by rapid cell death, as etoposide concentration increased. In contrast, resistant cell lines, such as MCF7, switched to single p53 pulses at high drug dose, which mostly triggered cell-cycle arrest but not cell death. To unravel the mechanistic basis underlying cell-type variation in p53 dynamics and its role in drug resistance, we combined single cell imaging, ensemble profiling and computational modeling. Our results revealed a multi-component control of coupled feed-forward and feedback involving ATM, p53, Mdm2 and Wip1, which can activate differential p53 dynamics and drug response in a cell-type specific manner. And our data also revealed network perturbations that can revert drug resistance and could be developed into therapeutic strategies.
Results

Cell-type variation in p53 dynamics and cellular response
Etoposide is a DNA damaging chemotherapeutic commonly used in the clinic and triggers DNA double-stranded breaks by inhibiting topoisomerase II [20] . We first compared dose response of an etoposide-sensitive (U-2 OS) and resistant cell line (MCF7), and their respective drug-induced p53 dynamics. Both lines have wild-type p53. To monitor real-time p53 dynamics in individual cells, we used clonal fluorescent reporter cell lines that stably express a p53-Venus construct (i.e. wild-type p53 tagged with a yellow fluorescent protein, Venus) [13] .
Dynamics of the p53-Venus construct have been confirmed to behave similarly to its wild-type counterpart in both U-2 OS and MCF7 in previous studies [13, 15] . Time-lapse imaging of the fluorescent reporter lines showed that upon drug treatment, the fluorescent signal of p53-Venus mostly localized in the nucleus, and the time course of p53 fluorescence quantified by integrating Venus fluorescence in the nucleus showed a dose-dependent bimodal regulation ( Fig. 1a and 1b) .
At low drug dose (1µM -10µM), nuclear p53 mostly exhibited periodic pulsing followed by cell-cycle arrest in both cell lines. As etoposide concentration, and the extent of DNA damage, increased, p53 switched from periodic pulsing to different modes that varied between cell lines.
High etoposide activated monotonic induction of p53 in U-2 OS cells, with peak level 5-10 fold higher than the amplitude of the pulsing mode ( Fig. 1a ). In contrast, MCF7 cells switched to a single p53 pulse, with an amplitude 2-3 fold higher than that at low dose and a period about 1.5 fold longer (Fig. 1b) . These single-pulse dynamics resulted in a substantially lower integrated induction level of p53 in MCF7 than U-2 OS cells under high drug.
Based on the time-lapse movies, we can score dose-dependent cell fate response by morphological tracking (refer to Materials and Methods for details) and correlated p53 dynamics with the cell fate response in individual cells. We re-plotted dose response data previously published in reference [13] for U-2 OS cells in Figure 1c and 1d for direct comparison with the new data for MCF7 cells. These single cell statistics demonstrated that > 92% MCF7 cells (summed over all drug concentrations) that showed periodic pulsing of p53 went into cell-cycle arrest (Fig. 1c ). The strong correlation between oscillatory p53 and cell-cycle arrest is similar to our previous observation in U-2 OS cells, further indicating the role of p53 oscillation in restraining p53 induction level and pro-apoptotic activity so as to render cell-cycle arrest that allows damage repair at low DNA damage. As etoptoside concentration increased, both U-2 OS and MCF7 showed increase of cell death, but MCF7 cells were much less sensitive to etoposideinduced cell death than U-2 OS cells ( Fig. 1d The observed resistance of MCF7 cell to drug-induced cell death, even in response to very high concentration of etoposide, correlated with the significantly lower p53 induction level rendered by the single-pulse dynamics of p53, as compared to the strong monotonic increase seen in U-2 OS ( Fig. 1a & 1b) . Among MCF cells that showed single-pulse p53, 80% were found to go into cell-cycle arrest, while the other 20% died. The induction level of single-pulse p53 was obviously not sufficient to cross the threshold for triggering cell death for the majority of MCF7 cells. This observation further indicated the suppressive role of p53 pulsing in attenuating p53 induction level and subsequent cell death. Note that although the MCF7 cells are isogenic, the threshold for triggering cell death may still vary between individual cells, e.g., due to stochasticity in gene expression [21, 22] . Therefore, cell-to-cell variability in sensitivity to cell death coupled with the intermediate level of p53 induction resulted from single-pulse p53 likely account for p53 inducing alternative cell fate of arrest and death in individual cells. Overall, the observation of cell line-dependent regulation of p53 dynamics and its correlation with differential drug response, in particular the cell death response, point to the importance of bimodal p53 dynamics in regulating sensitivity of distinct cancer cells to DNA damaging chemotherapeutics.
Cell line variation in p53 dynamics at high drug concentration correlates with differential levels of phospho-ATM, Mdm2 and Wip1
To explore the molecular mechanism underlying dose-dependent bimodal regulation of p53 dynamics as well as its cell-type dependence, we profiled, by western blotting, the level of expression and/or post-translational modification of key regulators that are known to modulate p53 expression and activity, including ATM, Chk2, Mdm2 and Wip1 [9, [23] [24] [25] . We chose to compare cellular responses at one low (i.e., 1µM etoposide for U-2 OS and 5µM for MCF7) and one high drug concentration (i.e., 100µM etoposide for U-2 OS and 200µM for MCF7) for each cell line, under which cells largely exhibited the same p53 dynamics, i.e. periodic pulsing at low drug and monotonic increase or single pulse at high drug. We performed the western blots at 4 time points after etoposide addition, and ran gels either with the two different drug concentrations side by side for one cell line ( Fig. 2a & 2b ), or different cell lines side by side for the same dose range ( Fig. 2c & 2d ), to allow quantitative comparisons. Figure 2a and 2b, in both U-2 OS and MCF7 cells, higher drug concentration induced higher level of p53, similar to data from single cell imaging (DNA damage level was indicated by γH2A.X, a double-stranded break reporter). And higher p53 level correlated with higher p53 activity in activating its transcriptional targets, such as p21 (cell-cycle Figure 2c and 2d further confirmed the differential expression of Mdm2 and Wip1 in U-2 OS and MCF7. It also revealed a much lower level of total ATM and thus lower level of phospho-ATM, but higher basal expression of Wip1, in MCF7 than U-2 OS, which may also contribute to the attenuated p53 induction in the form of single pulse in MCF7 at high drug. We note the level of DNA damage engendered by etoposide in the same dynamical regime, as indicated by the γH2A.X signal, was largely similar in U-2 OS and MCF7 ( Fig. 2c and 2d) . Therefore, the cell line-dependent dynamics of p53 and its regulators were not due to difference in the input DNA damage signal induced by etoposide, but rather variable activation of the p53 regulatory pathway.
As shown in
ATM-mediated Mdm2 degradation accounts for cell line-specific Mdm2 attenuation at high drug concentration
Given the level and dynamics of phospho-ATM, Mdm2 and Wip1 correlated with bimodal p53 dynamics as well as cell-type variation, we next examined their mechanistic involvement in regulating p53 induction. We had previously shown that in U-2 OS cells, attenuation of Mdm2 activity alone, by either gene knockdown or a small-molecule Mdm2 inhibitor, Nutlin-3, was sufficient to change not only p53 dynamics from oscillation to monotonic increase but also cellular response from cell-cycle arrest to cell death [13] . The data thus suggest differential Mdm2 up-regulation modulated by DNA damage level is the major regulator of bimodal p53 dynamics in U-2 OS cells, with Wip1 playing a negligible role in this regard. The fact that U-2 OS cells express significantly less Wip1 than MCF7 cells also pointed to a relatively minor role of Wip1 in U-2 OS, as compared to MCF7.
Suppression of Mdm2 up-regulation in U-2 OS at high drug concentration (i.e., high DNA damage level), which was not seen in MCF7 cells, could be due to reduced gene transcription or translation, or increased protein degradation. We had previously performed quantitative real-time PCR (qPCR) analysis and found no differential transcription of the Mdm2 gene at low vs. high DNA damage in U-2 OS cells [13] , indicating post-transcriptional mechanism likely accounts for the dose-dependent Mdm2 expression. DNA-damage kinases, such as ATM, had been observed to promote auto-degradation of Mdm2 [26] , which led us to hypothesize that the strong elevation of phosphon-ATM activity in response to high drug may trigger more extensive phosphorylation of Mdm2, thus promoting its auto-degradation and restraining Mdm2 expression close to the basal level. To determine whether Mdm2 degradation is enhanced at high etoposide concentration and whether this degradation process is ATM dependent, we measured the half-life of Mdm2 protein in U-2 OS cells by western blotting, using cycloheximide to inhibit overall protein translation. As shown in Figure 3a 
where imaging experiments ( Fig. 4a and 4b ). p53 oscillation is activated in both U-2 OS and MCF7 cells at low drug, where steady states lose stability and limit cycles appear in the bifurcation diagram ( Fig. 4c ). Under high etoposide concentration, the steady-state p53 in U-2 OS cells can reach a high level because the high level of ATM p strongly phosphorylates Mdm2 and promotes its degradation. Mdm2 thus remains largely at the basal level, allowing p53 to accumulate to a high level (Fig. S1) . In contrast, the steady state of p53 in MCF7 only rises slightly at high drug ( Fig. 4c ). Hence, p53 tends to return to a low level after transient elevation, resulting in the dynamic mode of a single pulse. This dynamic mode can be explained by low ATM p activity due to the low level of total ATM in MCF7, which is insufficient to enhance Mdm2 degradation significantly. As Mdm2 degradation does not outweigh its production, Mdm2 increases to a high level after a rapid degradation, which drives p53 back to a low level and keeps it at that low level ( Fig. S1 ).
Using this model, we were able to computationally investigate the quantitative dependence of p53 dynamics on ATM, Mdm2 and Wip1 in response to high etoposide concentration, where U-2 OS and MCF7 differ. To distinguish dynamics of monotonic increase and single pulse, we first defined a quantity as follows to quantify the degree, to which p53 dynamics resemble a typical single pulse,
As shown in the inset of Figure 4d , 0 is the initial level of p53 (i.e., steady-state value under no drug treatment), max is the maximal p53 level induced by etoposide, and ss is the steady-state level of p53 under drug. Note that = 1 indicates that p53 dynamics are monotonic increase and > 1 indicates a single pulse. A larger corresponds to p53 dynamics with features closer to a typical single pulse. We first simulated p53 dynamics for U-2 OS cell under perturbations of total ATM (ATM t ) and the production rates of Mdm2 ( m0 and pm ) and Wip1 ( w0 and pw ), by increasing or decreasing their original values by folds. Notably, reducing total ATM or increasing the transcription rates of Mdm2 and Wip1 can change p53 dynamics in U-2 OS from monotonic increase to a single pulse, indicating these are viable routes to evolve drug resistance.
Moreover, decrease of total ATM exhibits a greater effect on altering p53 dynamic than increasing the production rates of Mdm2 and Wip1, further validating that ATM expression, which determines the activation level of the positive feed-forward of ATM-Mdm2-p53, is the most critical factor that controls cell-type variation in p53 dynamics.
Next we simulated how p53 dynamics can be altered from single pulse to monotonic induction in MCF7 cells ( Fig. 4e and 4f ). 
Sensitization of MCF7 cells to drug-induced cell death by modulation of p53 dynamics
To Further western blot analysis confirmed not only the single cell imaging results regarding differential p53 dynamics and cell death response in MCF7 cells but also that higher p53
induction level corresponded to higher p53 activity, e.g., in up-regulating p21 (Fig. 5c and 5d ).
Moreover, it showed that Wip1 knockdown strongly enhanced p53 phosphorylation, e.g., at
Serine 15 and Serine 46. Phosphorylation of p53 at Serine 15 is known to stabilize p53 [10, 27] , and phosphorylation at Serine 46 particularly activates the transcription activity of p53 to upregulate pro-apoptotic genes [28] [29] [30] . Therefore, the negative feedback of Wip1-p53 likely attenuates p53 induction level by destabilizing p53 and further decreases cell death response to etoposide by attenuating p53 transcriptional activation of pro-apoptotic genes.
Discussion
Our study not only elucidates a dynamic mechanism underlying variable sensitivity to DNA damaging drug but also provides new insight to understand cell-type variation in p53 pathway-mediated DNA damage response. Variation in cell death response to cytotoxic chemotherapy is possibly the most crucial factor that distinguishes sensitive and resistant tumors, as clinical response of tumor regression or delay in tumor growth often correlates with the cell death response [31, 32] . Our data showed that the dynamic mode of p53 induction, especially at regime of high concentration of DNA damaging drug (i.e., high level of DNA damage), determines the sensitivity of p53-wild-type cancer cells to drug-induced cell death. Resistance to the cell death response arises from mechanism not due to obvious genetic mutation, but through attenuating the output of a collective regulatory module that controls p53 dynamics. In MCF7 cells, the modular output is damped mainly by down-regulating ATM. We suspect perturbations of other modular features (e.g., enhancement of Mdm2 and Wip1 transcription rates) or additional regulatory components beyond this core module, which promote pulsing p53 upon drug treatment, may contribute to drug resistance of other tumor types. Our results also suggest combinatorial targeting of Mdm2 and Wip1 is a promising strategy to combat this type of drug resistance.
The fact that we found down-regulation of ATM reduced sensitivity to DNA damaging drug puts a cautious note on combining ATM inhibitor with DNA damaging chemotherapeutics for cancer treatment [33] . Loss of ATM activity was first found to sensitize cells to ionizing radiation (IR), sparking the interest to develop ATM inhibitor as anticancer drug, particularly as combinatorial therapy with IR and DNA damaging drugs [34] . Early data showed tumor cells with defective p53 was more pronouncedly sensitized by ATM inhibitor to IR and chemo-drugs [35, 36] , while a recent study concluded the sensitizing effect was significant in both p53-wildtype and p53-defficient cells [37] . It remains unclear whether and how the functional status of p53 affects response to ATM inhibitor. Our study showed attenuation of ATM activity desensitizes, rather than sensitizes, the response of p53-wild-type cancer cells to DNA damaging drug. Although down-regulation of ATM activity may not give rise to exactly the same phenotypic response as that of complete inhibition of the kinase, our results do argue against combining ATM inhibitors with chemo-drugs for tumors with wild-type p53.
By exploring a large range of DNA damage dose, we characterized p53 dynamics and drug response at a dynamical regime that is more associated with cell death. The typical etoposide dose used in patients is 100mg/m 2 /day, which results in a peak plasma drug concentration of about 20µg/ml, i.e., 34µM [38] . As shown in Figure 1d , this dose level of etoposide is sufficient to activate monotonic p53 induction and cell death in 60-80% of U-2 OS cells, suggesting the dose response of U-2 OS is possibly informative of sensitive tumors in the clinical context. At the same dose level, less than 5% cell death was induced in MCF7, validating it as a model for resistant cancer. The resistance mechanism that we elucidated for MCF7 may help to guide identification of some resistant tumors. Less clear is how normal cells respond to etoposide at this treatment dosage. In order for the cytotoxic therapy to work, a favorable efficacy-to-toxicity ratio ('therapeutic index') has to be achieved, i.e., the drug needs to kill tumor without killing the patient. Normal cells obviously have wild-type p53, and our results suggest that retraining p53 dynamics to the pulsing mode protects cells from drug-induced cell death. We do not yet know how the regulatory module that controls p53 dynamics differs between normal and cancer cells and whether it is possible to develop combinatorial target that can achieve a better therapeutic index, e.g., by protecting normal cells or sensitizing cancer to respond to lower drug dose. Nonetheless, our results point to modulation of p53 dynamics as a new possible angle to explore new drug target and drug combination.
On the basic biology of signaling molecule dynamics and pathway control, our data provide new evidence that a major function of p53 pulsing, both in the form of periodic pulsing and single pulse, is to suppress p53 induction level and its activity to trigger cell death. At time of low DNA damage, p53 oscillation retrains p53 induction and its pro-apoptotic activity at low level, which allows damage repair and cell survival. Upon high DNA damage, single-pulse p53 prevents p53 induction to a high level that can activate rapid and extensive cell death, again enabling cell survival despite massive DNA damage. Periodic pulsing of p53 dynamics is extensively characterized before, with most studies attributing it to a time-delay negative feedback loop between p53 and Mdm2 [39, 40] . The dynamic mode of single-pulse p53 was also previously analyzed for MCF7 cells in response to transient UV irradiation and was attributed to differential activation of the phosphatase, Wip1 [18] . However, our results showed Wip1 did not play a significant role in engendering single-pulse p53 in the model system that we studied. Both experimental and computational analysis of the ATM/p53/Mdm2/Wip1 regulatory module showed attenuation of the positive feed-forward loop of ATM-Mdm2-p53 is the key to generate suppressive single-pulse p53 dynamics at high DNA damage. It appears mechanisms that activate even the same p53 dynamic mode could differ depending on the stimulus. To unravel how the regulatory module that controls p53 dynamics may be differentially activated in a stimulus-dependent manner, we will need to investigate and compare single-cell p53 dynamics in response to a wider variety of stimuli, such as ribosomal stress and hypoxia, in follow-up studies.
Materials and Methods
Cell culture Cell lines were purchased from American Type Culture Collection (ATCC, USA) and cultured under 37°C and 5% CO 2 in appropriate medium supplemented with 10% Fetal Calf Serum (FCS), 100U/ml penicillin and 100µg/ml streptomycin. U-2 OS was maintained in 
